Supplementary Information

Figure S1. Co-incubation of A2780cis cells with cisplatin and MMP-9/MMP-2i for 6 hours. Simultaneous monitoring of changes in (A) cell density, (B) cell membrane permeability, (C) lysosomal mass/pH, (D) nuclear condensation/intensity and (E) nuclear size following co-incubation of A2780cis cells with cisplatin and MMP-9/MMP-2i for 6 h. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), * p < 0.05, ** p < 0.01, *** p < 0.001. Experiments were carried out in triplicates.
Figure S2. Pre-incubation of A2780cis cells with MMP-9/MMP-2i for 3 h followed by cisplatin for 6 h. Simultaneous monitoring of changes in (A) cell density (B) cell membrane permeability (C) lysosomal mass/pH (D) nuclear condensation/intensity and (E) nuclear size following pre-incubation of A2780cis cells with MMP-9/MMP-2i for 3 h followed by treatment with cisplatin for 6 hs. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), ** p < 0.01, *** p < 0.001. Experiments were carried out in triplicates.
Figure S3. Co-incubation of A2780 cells with cisplatin and MMP-9/MMP-2i. Simultaneous monitoring of changes in (A) cell density (B) cell membrane permeability (C) lysosomal mass/pH (D) nuclear condensation/intensity and (E) nuclear size following co-incubation of A2780 cells with cisplatin and MMP-9/MMP-2i for 3 h. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure S4. Pre-incubation of A2780 cells with MMP-9/MMP-2i for 3 h followed by cisplatin treatment. Simultaneous monitoring of changes in (A) cell density (B) cell membrane permeability (C) lysosomal mass/pH (D) nuclear condensation/intensity and (E) nuclear size following pre-incubation of A2780 cells with MMP-9/MMP-2i for 3 h followed by treatment with cisplatin for 3 h. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), ** p < 0.01, *** p < 0.001.
Figure S5. Co-incubation of A2780 cells with cisplatin and MMP-9/MMP-2i for 6 h. Simultaneous monitoring of changes in (A) cell density (B) cell membrane permeability (C) lysosomal mass/pH (D) nuclear condensation/intensity and (E) nuclear size following co-incubation of A2780 cells with cisplatin and MMP-9/MMP-2i for 6 h. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), * p < 0.05, ** p < 0.01, ***p < 0.001. Experiments were carried out in triplicates.
**Figure S6.** Pre-incubation of A2780 cells with MMP-9/MMP-2i for 3 h followed by cisplatin for 6 h. Simultaneous monitoring of changes in (A) cell density (B) cell membrane permeability (C) lysosomal mass/pH (D) nuclear condensation/intensity and (E) nuclear size following pre-incubation of A2780 cells with MMP-9/MMP-2i for 3 h followed by treatment with cisplatin for 6 h. Values were normalised to vehicle treated wells. Representative data are shown as means ± SE (n = 3), **p < 0.01, ***p < 0.001. Experiments were carried out in triplicates.
**Figure S7.** MMP-9 protein expression evaluated by immunohistochemistry in a recurrent serous papillary ovarian adenocarcinoma (20×).

**Figure S8.** ELISA results of MMP-9 and TIMP-2 concentrations in serum samples. Sample population included serum from benign ovarian cystadenomas, borderline serous ovarian tumours, serous papillary adenocarcinomas of the ovary and recurrent serous papillary adenocarcinomas ($n = 39$).

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).